J. Pharm. Tech. Res. Management Vol. 12, No. 1 (2024), pp.70–83

CHITKARA

Journal of Pharmaceutical Technology Research and Management
Journal homepage: https://jptrm.chitkara.edu.in/

Understanding the Role of Muscle Coordination Impairments in Central Nervous System Disorders

Josephat Gaudence Kipesha[1], Harshpreet Kaur[1], Navneet Khurana[1*] and Neha Sharma[1]

[1]*School of Pharmaceutical Sciences, Lovely Professional University, Phagwara (144411), Punjab, India.*

[*]navi.pharmacist@gmail.com (Corresponding Author)

ARTICLE INFORMATION

Received: 03 January, 2024
Revised: 05 February, 2024
Accepted: 10 March, 2024
Published Online: 20 April, 2024

Keywords:
Neurodegeneration, Muscle tension, Coordination, Motor unit, Effector, Motor impairment, Deterioration

DOI: 10.15415/jptrm.2024.121006

ABSTRACT

Background: The central nervous system (CNS) regulates the precise activation of motor units, which is vital for muscle coordination and goal-directed movement. The CNS modulates motor unit firing rates to control force production during muscle contraction. Many CNS diseases, such as Alzheimer's disease, Huntington's disease, Parkinson's disease, and anxiety-related disorders, are linked to abnormalities in muscle coordination.

Purpose: This review examines the complex connection between CNS disorders and impairments in muscle coordination, highlighting the roles of motor performance, neurodegeneration, and cerebellar function.

Methods: A comprehensive review of recent literature was conducted to analyze the neurophysiological mechanisms underlying motor dysfunction. Studies involving kinematic analyses describing movement abnormalities in anxiety and depression were reviewed.

Results: Neurodegenerative processes contribute to muscular dysfunction, often occurring without anatomical alterations in muscle tissue. Declining motor performance and neurodegenerative changes suggest that early motor impairments may serve as potential indicators of CNS pathology.

Conclusion: Understanding the link between CNS disorders and muscle coordination impairments is crucial for distinguishing drug-induced muscular effects from symptoms of neurological diseases, guiding the development of more targeted treatments.

1. Introduction

Muscle coordination is an intricate physiological process that involves the synchronization of the musculoskeletal and neurological systems to produce precise, intentional movements. The brain, spinal cord, peripheral motor units, and other components of the central nervous system (CNS) form a complex network that regulates it. This complex coordination is essential for preserving equilibrium, carrying out voluntary activities, and adjusting to environmental pressures. Through feedforward and feedback mechanisms (Halsband & Lange, 2006), the CNS regulates muscle coordination, varying motor unit firing rates to create smooth and efficient movements (Riley *et al.*, 2008).

Muscle coordination is severely disrupted by diseases of the CNS, such as neurodegenerative and psychological disorders (Lamptey *et al.*, 2022). Motor performance is particularly affected by conditions including Huntington's disease (HD), Parkinson's disease (PD), Alzheimer's disease (AD), and anxiety-related mental health disease (Buchman & Bennett, 2011). These disruptions can have a significant impact on patients' quality of life by causing symptoms like tremors, muscle rigidity, and poor motor abilities. The fundamental mechanisms that connect CNS diseases to muscle coordination are still not well known, despite the critical role that motor difficulties play in many diseases.

Motor coordination depends on the cerebellum (Zhang *et al.*, 2024), basal ganglia, and cortical motor regions, all of which are frequently impacted by CNS diseases. Figure 1 illustrates the structural relationship between the spinal cord, spinal nerves, motor neurons, and muscle fibers (Garcia-Retortillo *et al.*, 2023), which is crucial for understanding motor coordination and the neurophysiological basis of movement control. In addition, motor dysfunction is largely caused by neurodegeneration, neurotransmitter imbalances, and disrupted brain connections. Figure 2 illustrates the relationship between CNS disorders and muscle coordination, emphasizing how neurodegeneration and neurotransmitter imbalances contribute to motor

©Author(s) 2024. This article is published with open access at https://jptrm.chitkara.edu.in.
ISSN No.: 2321-2217(Print) ISSN No.: 2321-2225(Online); Registration No. : CHAENG/2013/50088

impairment and subsequent muscle coordination disorders (Duranti & Villa, 2024). For instance, neurofibrillary tangles in AD hinder motor planning and execution, whereas dopamine deficiencies in PD cause bradykinesia and rigidity. These pathophysiological alterations highlight the necessity of a thorough comprehension of the ways in which CNS diseases impact muscular coordination (Andrade-Guerrero *et al.*, 2024).



Figure 1: The Motor Unit



Figure 2: The Relation between CNS Disorders and Muscle Coordination

The complex link between CNS disorders and impairments in muscular coordination is the focus of this review. In order to fill in current knowledge gaps and offer suggestions for possible diagnostic and treatment approaches, this study examines disease-specific mechanisms and current developments. A thorough comprehension of these relationships is essential for enhancing patient care and creating focused treatments to lessen motor dysfunction in diseases of the CNS.

2. CNS Disorders Affecting Muscle Coordination

Muscle coordination is significantly impacted by diseases of the CNS, which disrupt the intricate balance between musculoskeletal function and neural control. These diseases can be broadly divided into neurodegenerative and psychiatric disorders, each of which has unique clinical characteristics and mechanisms (Birbeck *et al.*, 2015). Developing focused

diagnostic and treatment approaches requires an understanding of how CNS disorders interact with motor impairments.

2.1. Psychiatric Disorders

Psychiatric diseases may present with mild but debilitating deficits in motor coordination. The intricate relationship between emotional control and motor performance is highlighted by anxiety and depression in particular. As neurotransmitter imbalances and decreased neuroplasticity are strongly linked to depression, they affect motor planning and execution. These conditions demonstrate how emotional dysregulation can have a major effect on one's ability to perform physically, resulting in symptoms including fatigue, rigid muscles, and impaired coordination (Peralta & Cuesta, 2017).

2.1.1. Anxiety

Anxiety is pronounced to be the most frequent CNS disorder encountered in clinical practice (Parada *et al*., 2014). It is a condition of increased fear and concern that might be brought on by particular stressors or everyday challenges. It involves excessive and continuous fear or anxiety that stands in the way of day-to-day tasks. To describe anxiety behaviors, several genetic, behavioral, cognitive, psychoanalytic, biological, and psychodynamic theories have been put forth. Several anxiety behaviors include panic attacks with agoraphobia, social phobia, specific phobias, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), and generalized anxiety disorder (GAD) (Bystritsky *et al*., 2013).

- **Mechanisms: Amygdala Connectivity and Muscle Tension**

Anxiety disorders are characterized by elevated amygdala activity and changed functional connections with other brain regions, such as the cerebellum and prefrontal cortex. Increased muscular tension is a result of this dysregulation, which affects how fear is processed and how emotions are controlled (Rauch *et al*., 2003). While the amygdala's central nucleus governs species-specific fear responses through connections to the brainstem, hypothalamus, and cerebellum, the amygdala's basolateral complex processes sensory-related fear memories. The somatic signs of anxiety, such as tense and tight muscles, are caused by these pathways (Etkin *et al*., 2009). Studies have indicated that chronic muscle tension is linked to GAD (Bamalan *et al*., 2023), frequently acting as a distinguishing symptom. Long-term autonomic nervous system activity and elevated arousal levels cause this tension, which reflects the complex relationship between psychological stress and physical symptoms (Pluess *et al*., 2009).

- **Symptoms: Muscle Rigidity and Somatic Indicators**

Muscle rigidity, restlessness, and exhaustion are common somatic symptoms observed by patients with anxiety disorders. GAD is characterized by tense muscles, especially in the jaw, neck, and shoulders. These symptoms lead to a vicious cycle of worry and physical impairment by aggravating psychological distress in addition to physical discomfort. Research indicates a direct correlation between pathological concern and muscle tension, underscoring the diagnostic utility of this condition (Im *et al*., 2023).

- **Tools: Electromyography (EMG) in Assessment**

An effective method for evaluating muscular tension and activity in anxiety disorders is electromyography (EMG). EMG provides quantifiable information on muscular rigidity and general tension by measuring the electrical activity of muscles both during contraction and at rest. For instance, patterns of persistent tension linked to worry can be identified by measuring frontalis muscle activity (Carvalho *et al*., 2023). Subsequently, EMG-based clinical research has shown that biofeedback and relaxation methods can dramatically ease tense muscles in those who are nervous. When paired with medication, these methods present effective ways to manage the physical manifestations of anxiety disorders. Despite these developments, more investigation is required to clarify the exact processes via which anxiety affects muscular coordination and to improve diagnostic instruments for wider therapeutic use (Fazzari *et al*., 2023; Ferreira *et al*., 2024).

Additionally, one of the studies involving healthy individuals had shown a significant reduction in the level of anxiety after subsequent relaxation training in a regulated environment. These results assured reproducibility between individuals. Another study involving nervous individuals found that the significance of this association was not established. Hence, the relation between anxiety and muscle tension has some limitations. However, new studies propose that the link between anxiety and body tension is significant (Sabharwal, 2014). Additionally, muscle relaxants have proven effective in reducing anxiety levels. Yet, the exact mechanism by which muscle relaxants alleviate anxiety remains unclear.

2.1.2. Depression

Depression is a common mental health condition characterized by persistent feelings of sadness, diminished interest or enjoyment in activities, and a number of cognitive and physical symptoms that interfere with day-to-day functioning. Individuals with depression frequently experience fatigue, alterations in sleep patterns, and challenges with focus or decision-making (Iyer & Khan, 2012).

- **Mechanisms: Neurotransmitter Dysregulation and Motor Impairments**

Dysregulation of the noradrenergic, dopaminergic, and serotonergic systems (Moncrieff *et al*., 2023), all of which are essential for motor control, is strongly linked to depression. Neurotransmitter imbalances reduce motor functioning and execution by disrupting communication between motor regions, including the prefrontal cortex and basal ganglia. In addition, decreased neuroplasticity and synaptic connection have also been found in depressed people, which may exacerbate motor dysfunction (Namiot *et al*., 2024).

- **Symptoms: Fatigue, Muscle Weakness, and Coordination Deficits**

Muscle weakness, poor coordination, and persistent fatigue are common somatic signs of depressive disorders. Due to slower motor reflexes and decreased physical stamina, patients frequently report having trouble completing daily tasks (Dobrek & Głowacka 2023). Widespread musculoskeletal discomfort is a symptom of fibromyalgia, a disorder that frequently coexists with depression and worsens motor impairments (Giorgi *et al*., 2024).

- **Tools: Kinematic Analysis in Diagnosis**

A useful diagnostic technique for depression is kinematic analysis, which assesses motor function and movement patterns. Since motor impedance is an aspect of depression, using this tool, researchers were able to justify the antidepressant motor effect. To illustrate the connection between depression and fine motor performance, this tool was used in patients suffering from depression and compared to patients taking antidepressants. Irregular patterns in analysis were higher in depressed patients, depicting basal ganglia dysfunction and/or deficient activity of the sensorimotor cortex and the supplementary motor area as potential substrates of hand-motor instabilities in depressed patients (Mergl *et al*., 2007). Furthermore, in one speedy drawing program including 37 depressed and 37 healthy individuals, a graphic tablet for kinematic analysis was used. Both groups had equal distribution with regard to gender, age, and education level. The outcome from the study has shown that depressed subjects had slower motor performance. Depressed subjects had an abnormally slower enactment when copying complex figures as fast as possible (Mergl *et al*., 2007). These results illustrated that depressed subjects had lower mental performance and motor insufficiencies, which played a major role in this retardation (Du *et al*., 2020). These results highlight how useful kinematic analysis is for detecting motor deficits and tracking the effectiveness of treatment.

Moreover, the motor and psychological symptoms of depression can be alleviated by new treatments such as cognitive-behavioral therapies coupled with exercise. To maximize these strategies and comprehend the reciprocal association between mood disorders and motor coordination deficiencies, more research is necessary (Abdollahi *et al*., 2017).

2.2. Neurodegenerative Disorders

Neurodegenerative diseases are progressive, chronic conditions that cause neurons to deteriorate. Because of anatomical and functional abnormalities in the CNS, these diseases severely impair muscular coordination. Patients' quality of life is greatly diminished as a result of the impairment of neuronal health, which affects motor planning, execution, and overall performance. The three most researched neurodegenerative diseases that impact motor coordination are HD, PD, and AD (Dugger & Dickson, 2017).

2.2.1. Alzheimer's Disease

AD is a neurodegenerative disease that starts slowly and exacerbates over time. It can result in a partial or severe loss of memory and cognitive abilities like thinking, reasoning, and social behavior (Mani *et al*., 2022). Usually results in impairing a person's normal life, bringing difficulties in interaction and communication (McMaster *et al*., 2024; Tchekalarova & Tzoneva, 2023). Symptoms may vary, but the most common and noticeable is the inability to remember conversations (forgetfulness) and recall familiar routes (Andrade-Guerrero *et al*., 2023). AD can manifest as poor reasoning, failure to make simple judgments, and difficulty in speaking or reading.

- **Gray and White Matter Integrity**

In addition to being frequently linked to memory loss and cognitive decline, AD also severely impacts motor abilities (Hebert *et al*., 2011). Amyloid plaques and neurofibrillary tangles are pathological characteristics that lead to the gradual atrophy of gray matter in important areas such as the frontal cortex and hippocampus. Planning and execution of motions are hampered by this deterioration. To make motor dysfunction even worse, white matter injuries also interfere with the neuronal connections between motor and sensory areas. These structural abnormalities have been linked in studies to challenges with fine motor skills, locomotion, and postural balance that worsen as the disease worsens (Baumgartner *et al*., 1998).

- **Imaging Biomarkers for Motor Impairments**

In order to detect motor-related abnormalities in AD, advanced imaging techniques are essential. Advanced imaging techniques such as Positron Emission Tomography

(PET), Magnetic Resonance Imaging (MRI), diffusion tensor imaging (DTI), and electrophysiology are used to analyze brain activity in both simple and complex tasks (Agosta *et al*., 2010; Halsband & Lange, 2006). Early structural and functional alterations can be detected with the use of modalities including PET, DTI, and MRI. For example, poor motor coordination and unstable gait are associated with decreased fractional anisotropy in white matter pathways. Additionally, these imaging indicators make it easier to stage diseases and assess treatment options for reducing motor deterioration (Oschwald *et al*., 2021; Zhai *et al*., 2020). Furthermore, in recent research, it has been demonstrated there is a significant link between AD and body mass index (BMI), suggesting that BMI is one of the first signs of AD, and when BMI is affected, a patient's muscle mass and body fat are considered affected to some extent. In morphological studies, a huge relation between muscular structural damage and lower muscular energy was discovered, and therefore, it resulted in lower performance. Dual-energy x-ray absorptiometry (DXA) or imaging modalities can be used to assess muscle mass for this purpose (Verdijk *et al*., 2010).

Additionally, execution actions of the motor unit are performed by muscle (effector organ); thus, any impairment to the CNS or PNS would partially or completely affect muscle tone without changing muscular integrity. Thus, assessing muscle structure is crucial to clarify the primary decrease in muscle performance in AD (Hairi *et al*., 2010). Numerous studies have demonstrated the relationship between low grasping strength and chances of developing AD (Buchman *et al*., 2007). In one research study, axial and appendicular strength was determined, the outcomes of which proposed the association of AD with a decline in strength. Thus, from different perspectives, we can link reduced strength and impaired muscle structure as a primary reason for declining muscle performance and a prerequisite for AD, as well as a decline in cognition (Boyle *et al*., 2010).

2.2.2. Parkinson's Disease

PD is regarded as a slowly progressive CNS degenerative condition characterized by a number of motor and non-motor symptoms (Jankovic, 2008). It mainly results from the degeneration of dopaminergic neurons in the substantia nigra, an essential area of the basal ganglia. PD causes movement impairment, which results in affecting the usual functioning of an individual. Though PD can be connected to a variety of primary indicators, fewer symptoms are spotted early and commonly experienced by many patients. These symptoms for PD can be categorized into motor and non-motor symptoms. Motor symptoms affect movement, including tremor (a rhythmic shaking), rigidity or stiffness (inelasticity) of the muscles, akinesia, hypokinesia, postural instability, and slowness of movement (bradykinesia). Bradykinesia, akinesia, tremor, and muscle stiffness have been known to respond to dopamine therapy and hence are described as a hallmark of the disease (Ferreira & Massano, 2017; Tinelli *et al*., 2016). Many patients with PD may experience problems with walking, coordination, posture, and balance. Most common non-motor symptoms of PD include depression, constipation, fatigue, and anxiety (American, 2016).

- **Neurodegeneration and muscular coordination**

The association between neurodegeneration and muscular performance is well established in several studies. In PD, motor symptoms can be explained in expressions of motor coordination, which depict movement, limb locus, and speed of movement. As the disease's progression results in the death of neurons in the pars compacta region of the substantia nigra, one of the nuclei that constitute the basal ganglia (BG). These neurons are responsible for the transition of dopamine to another BG nucleus (Gamborg *et al*., 2023; S. Zhai *et al*., 2023). Hence, the death of these neurons causes impairment of these neuronal circuits that include the BG and motor cortical areas. As a result of these changes, patients' posture and gait are impaired (Mazzoni *et al*., 2012). Also, the balance between excitatory and inhibitory pathways in the basal ganglia is disrupted when dopamine levels are low, which is crucial for controlling smooth and precise motor activities. This leads to impaired motor coordination, delayed initiation of movement, and a loss of fine motor control (Kravitz *et al*., 2013).

- **Impact on Muscle Coordination**

Alterations in motor unit recruitment and firing patterns in PD have a substantial impact on muscle coordination. When dopamine signaling is disturbed, it impairs motor planning and execution, leading to bradykinesia, or slowness of movement. Another characteristic of PD is rigidity, which limits the range of motion and fluidity of movement and is caused by hyperactivity in stretch reflexes and increased muscle tone (Wichmann & Dostrovsky, 2011). These alterations show up as trouble completing activities like writing or buttoning garments that call for precise and coordinated muscle movement.

A late-stage PD symptom that increases the risk of falls is postural instability, which is brought on by an inability to integrate motor responses with sensory feedback. Different research indicates people with PD exhibit shorter strides, shuffled steps, and a difficulty to effectively change their movement's direction or speed (Guo *et al*., 2022). The quality of life is greatly impacted by this steady decline in motor functioning (Dalise *et al*., 2020).

2.2.3. Huntington's Disease

HD is a hereditary disorder causing neurodegeneration resulting from extension of a polyglutamine expansion within the huntingtin protein (HTT) (Rana *et al*., 2024). Neurological indications, which include cognitive, motor, and psychiatric instabilities, are the result of neuron degeneration, which predominantly spreads in the basal ganglia and cerebral cortex (Chaganti *et al*., 2017). Patients suffering from HD have shown several peripheral organ dysfunctions after having severe weight loss, HD-related cardiomyopathy, and skeletal muscle wasting (Wilson *et al*., 2017). A major symptom for HD is skeletal muscle wasting; despite being a major symptom, the mechanism underlying it remains unclear (Zielonka *et al*., 2014).

- **Striatal and Cortical Degeneration**

In HD, neurodegeneration usually extends to striatal nuclei, basal ganglia, and cerebral cortex, resulting in neurological symptoms including motor, cognitive, and psychiatric difficulties (McColgan *et al*., 2017; Novak & Tabrizi, 2010). This atrophy severely damages fine motor skills and voluntary motor control. Motor coordination becomes much more challenging as the disease progresses and individuals develop chorea (erratic, uncontrollable movements) and dystonia (sustained muscle spasms). These clinical features, including behavior alteration, motor difficulties, dementia, and weight decline, generally progress over 15 years until the individual succumbs to the disease (Walker, 2007).

- **Skeletal Muscle Wasting and Mitochondrial Dysfunction**

HD is linked to peripheral symptoms such as mitochondrial dysfunction and skeletal muscle atrophy in addition to CNS deterioration. Physical impairment is exacerbated by diminished muscle mass and impaired energy metabolism, according to research. The significance of comprehensive treatment strategies that address both central and peripheral deficits is highlighted by these systemic consequences. In HD patients, addressing mitochondrial dysfunction may open the door to better motor coordination and general physical wellness (Burtscher *et al*., 2021). In one clinical study containing 6 groups of 20 people with HD, the patients were observed having lower muscular energy by 50% on average when compared to healthy individuals (Busse *et al*., 2008). Furthermore, different researchers have reported an abnormality in the mitochondrial performance of the CNS and skeletal muscles in Huntington's patients (Kasner *et al*., 2013). In two groups of subjects with symptomatic and presymptomatic HD, patients mitochondrial ATP release declines by 44% and 35%, respectively, on recovery from a workout. Moreover, they displayed significant deficiency in the mitochondrial oxidative metabolism, which could play a major part in the HD-related muscle impairment (Jędrak *et al*., 2017; Lodi *et al*., 2000).

Moreover, HD patients have shown a development of motor impairment progression over time (van Hagen *et al*., 2017). In most of these cases, the origin of motor insufficiency is not well understood. In a study of asymptomatic HD gene carriers and evident HD, a reaching exercise revealed movement jerkiness, which marked the progression of presymptomatic HD. Furthermore, in HD, external error can't be corrected, and therefore this feedback failure can affect movement termination, which portrays the motor control problems in premature HD (Burtscher *et al*., 2024).

2.3. Amnesia, Dementia, and Cognition

2.3.1. Amnesia: Impacts on Procedural and Motor Memory

Amnesia, either neurological or functional, can be described as having a problem acquiring new information and a partial or complete memory retention deficit (Ledoux & Cloutier, 2012). It is memory loss brought on by disease, trauma, or damage that affects the parts of the brain that process memories, including the hippocampus. Functional amnesia is known as a psychiatric disorder, without the involvement of a specific brain structure or area whose impairment is recognized for triggering the illness (Berry & Shanks, 2024). On the other hand, neurological amnesia is the outcome of bilateral impairment to areas of the brain, crucial for memory storage, processing, or retention (the limbic system, involving the hippocampus in the medial temporal lobe) (Smith *et al*., 2013). In addition, it can also stem from different neurodegenerative disorders that directly affect the body's general motor performance (Barrett, 2002). It is largely a cognitive illness, but when procedural memory is compromised, it can also have an indirect effect on motor coordination. Patients may have trouble walking or using tools, two activities that call for developed motor skills. Research indicates difficulties in relearning fundamental movements following brain loss may result from amnesia that affects motor-related cortical areas.

2.3.2. Dementia: Cognitive Decline and Motor Impairments

Dementia is a gradual neurodegenerative condition characterized by cognitive and functional decline. It is often characterized by negative change in learning patterns, compromised balance, impaired coordination, and physical strength (Alzheimer's Society, 2012). It often involves damage to specific brain areas linked to motor unity, affecting motor coordination and walking patterns. Dementia is a general

term for the loss of memory and other cognitive abilities serious enough to interfere with daily life and performance. It is a precursor for AD, PD, and HD. Dementia can be of several types depending on the cause and region of the brain affected; other forms include vascular dementia, mixed dementia, Parkinson's disease dementia, dementia with Lewy bodies, and Huntington's disease dementia (Keefover, 2013).

Subsequently, the widespread neuronal atrophy causes motor impairments such as gait instability, decreased postural control, and coordination deficiencies in diseases like Alzheimer's-related dementia. These symptoms are made worse by the degradation of white matter and cortical areas involved in motor planning. For instance, balance and fine motor control are affected, which has a major influence on day-to-day activities, when the frontal cortex and motor pathways are no longer connected (Aggarwal *et al*., 2006; Sayyid *et al*., 2024).

Furthermore, one of the rare forms of dementia starts with the development of abnormal structures called Lewy bodies within the brain cells. These cells interrupt the chemistry of the brain, which leads to the loss of neurons. Common symptoms usually include hallucinations and complications in judging distances. A patient memory is usually affected less than in the early stages of AD. Dementia with Lewy bodies shares significant overlap with PD, notably with some similar symptoms, including trouble with walking patterns (Albers *et al*., 2015).

2.3.3. Cognition

Cognition can be described as the mental process of perception, which involves features like reasoning, awareness, and judgment. Cognition is the activity of understanding, the attainment, association, and application of information (Brandimonte *et al*., 2006)**.** During cognition, a repeated task that brings about skills learning results in different cortical activation patterns. These patterns provide unique sequences that do not depend on average activity alterations assessed by functional magnetic resonance imaging readings (Wiestler & Diedrichsen, 2013).

Furthermore, the relationship between motor skills and cognition is now a vital area of study, gaining attention day by day (Wang *et al*., 2023). Research was established to study the link between motor skills, cognitive utility, and academic performance. The study was conducted on 45 subjects ranging between 8 and 14 years of age; the link was associated between motor coordination, academic performance, and cognitive activity. These results depict the significance of various physical skills and cognitive tasks. The data indicated that visual motor coordination and visual selective attention, but not agility, can influence academic achievement and cognitive performance. These observations pointed out a positive relationship between physical skills and several cognitive characteristics (Fernandes *et al*., 2016).

3. Mechanisms of Motor De-Coordination in CNS Disorders

In CNS diseases, motor de-coordination results from complicated and multifaceted pathways that disrupt the delicate balance of brain regulation. These pathways include alterations to brain connectivity, neurotransmitter imbalances, synaptic loss, and neurodegeneration. It is crucial to comprehend these underlying issues in order to develop targeted approaches.

3.1. Neurodegeneration and Synaptic Loss

Progressive loss of neurons and synaptic connections is known as neurodegeneration, and it results in both structural and functional abnormalities in motor pathways. Specific neuronal populations are dying in diseases including AD (Jones *et al*., 2022), HD (Gil & Rego, 2008), and PD (Zeng *et al*., 2018), which impair motor planning and execution. For example, striatal degeneration in HD (Bano *et al*., 2011) inhibits voluntary movement control, while loss of dopaminergic neurons in PD affects basal ganglia function. Furthermore, synaptic loss impairs brain connection between motor areas, exacerbating motor dysfunction (Subramanian & Tremblay, 2021).

3.2. Dementia's Impact on Connectivity and Synapses

Motor performance is strongly impacted by synapse loss in cortical regions like the prefrontal cortex in dementia, especially Alzheimer's-related dementia. Increased gait variability and reduced muscle coordination are correlated with decreased connection between the motor cortex and cerebellum. Fine motor skills are further compromised by pyramidal neuron loss, making tasks like writing and handling small items challenging (Andrade-Guerrero *et al*., 2024; Scheff *et al*., 2014).

3.3. Neurotransmitter Imbalances

Dopamine, serotonin, and norepinephrine are among the neurotransmitters that are essential for motor coordination (Meltzer, 1998). When these substances are out of balance, motor units can't operate normally. Dopamine deficiency causes bradykinesia and rigidity in PD (Ramesh & Arachchige, 2023), whereas serotonergic dysregulation in depression results in motor fatigue and a decrease in physical endurance.

Pharmacological treatments to restore neurotransmitter balance continue to be a mainstay of care for motor deficits in CNS diseases (Teleanu *et al.*, 2022). Furthermore, acetylcholine levels, which are critical for synaptic plasticity and motor learning, are linked to dementia. Slower reaction times and impaired muscle coordination result from reduced cholinergic signaling in the basal forebrain, which also affects cognitive and motor integration (Haam & Yakel, 2017; Sabandal *et al.*, 2022).

3.4. Brain Connectivity Changes

An interconnected network that is essential for motor control is formed by the cerebellum, basal ganglia, and cortical motor regions (Bostan *et al.*, 2013; Larry *et al.*, 2024). These connections are frequently disrupted by CNS diseases, which hinders the integration of motor output and sensory input. For instance, while basal ganglia impairment in PD hinders movement initiation (Obeso *et al.*, 2009), abnormal cerebellar activity in anxiety impacts fine motor skills (Martins *et al.*, 2024). In addition, hippocampal-cortical circuit abnormalities impair motor memory and procedural learning in amnesia. Similarly, the default mode network and motor areas are less connected in dementia patients, which impacts adaptive motor responses and multitasking. Disruptions in brain connections that correlate with motor symptoms have been identified by advanced imaging techniques, providing information about disease processes and possible treatment targets (Ferguson *et al.*, 2019).

3.5. Differences across Disorders

Despite the fact that CNS diseases have basic causes such as neurodegeneration and neurotransmitter imbalances, each ailment displays distinct patterns of motor dysfunction. Cortical atrophy and white matter lesions cause motor difficulties in AD, whereas abnormalities in the circuits of the basal ganglia are a hallmark of PD. HD combines peripheral symptoms, including muscular atrophy, with striatal degeneration. Developing disease-specific therapies that meet the unique problems of each ailment requires an understanding of these characteristics.

Hence, the mechanisms underlying motor impairment in various CNS disorders are complex and multifaceted. Table 1 provides an overview of these mechanisms, detailing how neurodegeneration, neurotransmitter imbalances, and changes in brain connectivity contribute to motor dysfunction in different CNS diseases.

Table 1: Mechanisms by Which CNS Disorders Impair Motor Coordination

Sr. No.	CNS Disorder	Mechanism	Impact on Motor Coordination	References
1.	Anxiety	Hyperactivity in the amygdala; altered cerebellar activity	Muscle tension, rigidity, and impaired fine motor skills	(Pluess *et al.*, 2009)
2.	Depression	Dysregulation of serotonin and norepinephrine; reduced neuroplasticity	Fatigue, motor slowness, and reduced physical endurance	(Mostoufi *et al.*, 2012)
3.	Alzheimer's Disease (AD)	Neurofibrillary tangles; amyloid plaques; cortical atrophy; white matter lesions	Gait disturbances, reduced fine motor skills, and impaired balance	(Baumgartner *et al.*, 1998) (Boyle *et al.*, 2010)
4.	Parkinson's Disease (PD)	Dopaminergic neuron loss in substantia nigra; basal ganglia dysfunction	Bradykinesia, rigidity, tremors, and impaired gait and posture	(Jankovic, 2008)
5.	Huntington's Disease (HD)	Striatal and cortical degeneration; mitochondrial dysfunction	Chorea, dystonia, muscle weakness, and reduced coordination	(Zielonka *et al.*, 2014) (Wilson *et al.*, 2017)
6.	Amnesia	Disruptions in hippocampal-cortical pathways; impaired procedural memory	Difficulties in relearning motor skills and executing learned movements	(Barrett, 2002) (Laukkanen *et al.*, 2017)
7.	Dementia	Synaptic loss; acetylcholine depletion; reduced connectivity between motor networks	Gait instability, delayed motor responses, and impaired multitasking	(Keefover, 2013)
8.	Cognition	Impaired sensory integration, memory processing, and executive functions	Delayed motor learning, slower reaction times, and reduced adaptability	(Wang *et al.*, 2023)

4. Conclusion

Motor coordination is severely disrupted by diseases of the central nervous system, which affects functional independence and quality of life. The complex interactions between neurodegeneration, neurotransmitter imbalances, and altered brain connections in diseases like Parkinson's, Alzheimer's, Huntington's, amnesia, and dementia have been highlighted in this review. In addition, the integration of motor control and sensory input by cognition emphasizes the necessity of thorough diagnosis and treatment methods. New treatment approaches that show promise for treating cognitive and motor deficits include neurostimulation, customized medication delivery, and dual-task training. To improve patient outcomes, cognitive-motor integration must be incorporated into rehabilitation regimens. In order to lessen the complex effects of CNS diseases on motor coordination, future research should concentrate on improving these interventions and investigating cutting-edge strategies. Our knowledge of these processes and therapies will grow, opening the door to more individualized and efficient patient care.

Acknowledgements

The authors would like to thank all the researchers and authors whose work has been referenced in this article. Authors also extend the appreciation to colleagues and peers for their valuable insights and feedback that contributed to improving this review.

Authorship Contribution

Josephat Gaudence Kipesha: Conceptualization, methodology, and writing-original draft; Harshpreet Kaur: Validation, visualization, and reviewing; Dr. Navneet Khurana: Supervision and project administration; Dr. Neha Sharma: Investigation, data curation, and formal analysis

Funding

No funding has been received for this study.

Conflict of Interest

The authors declare no conflict of interest, financial or otherwise.

Declaration

The authors have no relevant financial or non-financial interests to disclose.

References

Abdollahi, A., LeBouthillier, D. M., Najafi, M., Asmundson, G. J. G., Hosseinian, S., Shahidi, S., Carlbring, P., Kalhori, A., Sadeghi, H., & Jalili, M. (2017). Effect of exercise augmentation of cognitive behavioural therapy for the treatment of suicidal ideation and depression. *Journal of Affective Disorders*, *219*, 58–63. https://doi.org/10.1016/j.jad.2017.05.012

Aggarwal, N. T., Wilson, R. S., Beck, T. L., Bienias, J. L., & Bennett, D. A. (2006). Motor Dysfunction in Mild Cognitive Impairment and the Risk of Incident Alzheimer Disease. *Archives of Neurology*, *63*(12), 1763. https://doi.org/10.1001/archneur.63.12.1763

Agosta, F., Rocca, M. A., Pagani, E., Absinta, M., Magnani, G., Marcone, A., Falautano, M., Comi, G., Gorno-Tempini, M.L. & Filippi, M. (2010). Sensorimotor network rewiring in mild cognitive impairment and Alzheimer's disease. *Human Brain Mapping*, *31*(4), 515–525. https://doi.org/10.1002/hbm.20883

Albers, M. W., Gilmore, G. C., Kaye, J., Murphy, C., Wingfield, A., Bennett, D. A., Boxer, A.L., Buchman, A.S., Cruikshanks, K.J., Devanand, D.P., Duffy, C.J., Gall, C.M., Gates, G.A., Granholm, A.C., Hensch, T., Holtzer, R., Hyman, B.T., Lin, F.R., McKee, A.C., Morris, J.C., & Zhang, L. I. (2015). At the interface of sensory and motor dysfunctions and Alzheimer's disease. *Alzheimer's and Dementia*, *11*(1), 70–98. https://doi.org/10.1016/j.jalz.2014.04.514

Alzheimer's Society. (2012). The later stages of dementia. In *dementia* (pp. 1–13).

American, P. D. (2016). *Parkinson's Disease HANDBOOK* (Vol. 10305). Medtronic.

Andrade-Guerrero, J., Martínez-Orozco, H., Villegas-Rojas, M. M., Santiago-Balmaseda, A., Delgado-Minjares, K. M., Pérez-Segura, I., Baez Cortes, M.T., Del Toro-Colin, M.A., Guerra Crespo, M., Arias-Carrion, O., Diaz-Cintra, S., & Soto-Rojas, L. O. (2024). Alzheimer's Disease: Understanding Motor Impairments. *Brain Sciences*, *14*(11), 1054. https://doi.org/10.3390/brainsci14111054

Andrade-Guerrero, J., Santiago-Balmaseda, A., Jeronimo-Aguilar, P., Vargas-Rodríguez, I., Cadena-Suárez, A. R., Sánchez-Garibay, C., Pozo-Molina, G., Mendez-Catala, C.F. Cardenas-Aguayo, M., Diaz-Cintra, S., Pacheco-Herrero, M., Lina-Munoz, J., & Soto-Rojas, L. O. (2023). Alzheimer's Disease: An Updated Overview of Its Genetics. *International Journal of Molecular Sciences*, *24*(4), 3754. https://doi.org/10.3390/ijms24043754

Bamalan, O. A., Alosaimi, N. M., Alfryyan, A. A., Aljubran, H. J., Alanazi, F. H., & Siddiqui, Z. I. (2023).

Generalized Anxiety Disorder: A Review of Current Literature in Saudi Arabia. *Psychology*, *14*(01), 35–51. https://doi.org/10.4236/psych.2023.141003

Bano, D., Zanetti, F., Mende, Y., & Nicotera, P. (2011). Neurodegenerative processes in Huntington's disease. *Cell Death & Disease*, *2*(11), e228–e228. https://doi.org/10.1038/cddis.2011.112

Barrett, J. (2002). Amnesia .*Blueprint for Health*, 1–5.

Baumgartner, R. N., Koehler, K. M., Gallagher, D., Romero, L., Heymsfield, S. B., Ross, R. R., Garry, P.J., & Lindeman, R. D. (1998). Epidemiology of Sarcopenia among the Elderly in New Mexico. *American Journal of Epidemiology*, *147*(8), 755–763. https://doi.org/10.1093/oxfordjournals.aje.a009520

Berry, C. J., & Shanks, D. R. (2024). Everyday amnesia: Residual memory for high confidence misses and implications for decision models of recognition. *Journal of Experimental Psychology: General*, *153*(7), 1790–1815. https://doi.org/10.1037/xge0001599

Birbeck, G. L., Meyer, A. C., & Ogunniyi, A. (2015). Nervous system disorders across the life course in resource-limited settings. *Nature*, *527*(7578), S167–S171. https://doi.org/10.1038/nature16031

Bostan, A. C., Dum, R. P., & Strick, P. L. (2013). Cerebellar networks with the cerebral cortex and basal ganglia. *Trends in Cognitive Sciences*, *17*(5), 241–254. https://doi.org/10.1016/j.tics.2013.03.003

Boyle, P. a, Buchman, A. S., Wilson, R. S., Sue, E., & Bennett, D. A. (2010). Association of muscle strength wirh the risk of Alzheimer's Disease and tje rate of cognitive decline in community-dwelling older persons. *Archives of Neurology*, *66*(11), 1339–1344. https://doi.org/10.1001/archneurol.2009.240

Brandimonte, M. A., Bruno, N., & Collina, S. (2006). *Cognition*.

Buchman, A. S., & Bennett, D. A. (2011). Loss of motor function in preclinical Alzheimer's disease. *Expert Rev Neurother.*, *11*(5), 665–676. https://doi.org/10.1586/ern.11.57

Buchman, A. S., Wilson, R. S., Boyle, P. A., Bienias, J. L., & Bennett, D. A. (2007). Grip strength and the risk of incident Alzheimer's disease. *Neuroepidemiology*, *29*(1–2), 66–73. https://doi.org/10.1159/000109498

Burtscher, J., Millet, G. P., Place, N., Kayser, B., & Zanou, N. (2021). The Muscle-Brain Axis and Neurodegenerative Diseases: The Key Role of Mitochondria in Exercise-Induced Neuroprotection. *International Journal of Molecular Sciences*, *22*(12), 6479. https://doi.org/10.3390/ijms22126479

Burtscher, J., Strasser, B., Pepe, G., Burtscher, M., Kopp, M., Di Pardo, A., Maglione, V., & Khamoui, A. V. (2024). Brain–Periphery Interactions in Huntington's Disease: Mediators and Lifestyle Interventions. *International Journal of Molecular Sciences*, *25*(9), 4696. https://doi.org/10.3390/ijms25094696

Busse, M. E., Hughes, G., Wiles, C. M., & Rosser, A. E. (2008). Use of hand-held dynamometry in the evaluation of lower limb muscle strength in people with Huntington's disease. *Journal of Neurology*, *255*(10), 1534–1540. https://doi.org/10.1007/s00415-008-0964-x

Bystritsky, A., Khalsa, S., Cameron, M., & Schiffman, J. (2013). Current diagnosis and treatment of anxiety disorders. *P&T®*, *38*(1), 30–57.

Carvalho, C. R., Fernández, J. M., del-Ama, A. J., Oliveira Barroso, F., & Moreno, J. C. (2023). Review of electromyography onset detection methods for real-time control of robotic exoskeletons. *Journal of NeuroEngineering and Rehabilitation*, *20*(1), 141. https://doi.org/10.1186/s12984-023-01268-8

Chaganti, S. S., McCusker, E. A., & Loy, C. T. (2017). What do we know about late onset Huntington's disease? *Journal of Huntington's Disease*, *6*(2), 95–103. https://doi.org/10.3233/JHD-170247

Dalise, S., Azzollini, V., & Chisari, C. (2020). Brain and Muscle: How Central Nervous System Disorders Can Modify the Skeletal Muscle. *Diagnostics*, *10*(12), 1047. https://doi.org/10.3390/diagnostics10121047

Du, Y., Gao, X. R., Peng, L., & Ge, J. F. (2020). Crosstalk between the microbiota-gut-brain axis and depression. *Heliyon*, *6*(6). https://doi.org/10.1016/j.heliyon.2020.e04097

Dugger, B. N., & Dickson, D. W. (2017). Pathology of Neurodegenerative Diseases. *Cold Spring Harbor Perspectives in Biology*, *9*(7), a028035. https://doi.org/10.1101/cshperspect.a028035

Duranti, E., & Villa, C. (2024). From Brain to Muscle: The Role of Muscle Tissue in Neurodegenerative Disorders. *Biology*, *13*(9), 719. https://doi.org/10.3390/biology13090719

Etkin, A., Prater, K. E., Schatzberg, A. F., Menon, V., & Greicius, M. D. (2009). Disrupted amygdalar subregion functional connectivity and evidence of a compensatory network in generalized anxiety disorder. *Archives of General Psychiatry*, *66*(12), 1361–1372. https://doi.org/10.1001/archgenpsychiatry.2009.104

Fazzari, C., Macchi, R., Ressam, C., Kunimasa, Y., Nicol, C., Martha, C., Bolmone, B., Sainton, B., Hays, A., Vercruyssen, F., Lapole, T., Bossard, M., Casanova, R., Bringoux, L., & Chavet, P. (2023). Neuromuscular adjustments to unweighted running: the increase in hamstring activity is sensitive to trait anxiety. *Frontiers in Physiology*, *14*. https://doi.org/10.3389/fphys.2023.1212198

Ferguson, M. A., Lim, C., Cooke, D., Darby, R. R., Wu, O., Rost, N. S., Corbetta, M., Grafman, J., & Fox, M. D. (2019). A human memory circuit derived from brain lesions causing amnesia. *Nature Communications*, *10*(1), 3497. https://doi.org/10.1038/s41467-019-11353-z

Fernandes, V. R., Ribeiro, M. L. S., Melo, T., de Tarso Maciel-Pinheiro, P., Guimarães, T. T., Araújo, N. B., Ribeiro, S., & Deslandes, A. C. (2016). Motor coordination correlates with academic achievement and cognitive function in children. *Frontiers in psychology*, *7*, 318. https://doi.org/10.3389/fpsyg.2016.00318

Ferreira, L. M. A., Brites, R., Fraião, G., Pereira, G., Fernandes, H., de Brito, J. A. A., Generoso, L.P., Maziero Cappelo, M.G., Periera, G.S., Scoz, R.D., Torres Silva, J.R., & Silva, M. L. (2024). Transcutaneous auricular vagus nerve stimulation modulates masseter muscle activity, pain perception, and anxiety levels in university students: a double-blind, randomized, controlled clinical trial. *Frontiers in Integrative Neuroscience*, *18*. https://doi.org/10.3389/fnint.2024.1422312

Ferreira, M., &Massano, J. (2017). An updated review of Parkinson's disease genetics and clinicopathological correlations. *Acta Neurologica Scandinavica*, *135*(3), 273–284. https://doi.org/10.1111/ane.12616

Gamborg, M., Hvid, L. G., Thrue, C., Johansson, S., Franzén, E., Dalgas, U., & Langeskov-Christensen, M. (2023). Muscle Strength and Power in People With Parkinson Disease: A Systematic Review and Meta-analysis. *Journal of Neurologic Physical Therapy*, *47*(1), 3–15. https://doi.org/10.1097/NPT.0000000000000421

Garcia-Retortillo, S., Romero-Gómez, C., & Ivanov, P. Ch. (2023). Network of muscle fibers activation facilitates inter-muscular coordination, adapts to fatigue and reflects muscle function. *Communications Biology*, *6*(1), 891. https://doi.org/10.1038/s42003-023-05204-3

Gil, J. M., & Rego, A. C. (2008). Mechanisms of neurodegeneration in Huntington's disease. *European Journal of Neuroscience*, *27*(11), 2803–2820. https://doi.org/10.1111/j.1460-9568.2008.06310.x

Giorgi, V., Sarzi-Puttini, P., Pellegrino, G., Sirotti, S., Atzeni, F., Alciati, A., Torta, R., Varassi, G., Fornasari, D., Coaciolli, S., & Bongiovanni, S. F. (2024). Pharmacological Treatment of Fibromyalgia Syndrome: A Practice-Based Review. *Current Pain and Headache Reports*. https://doi.org/10.1007/s11916-024-01277-9

Guo, Y., Yang, J., Liu, Y., Chen, X., & Yang, G.Z. (2022). Detection and assessment of Parkinson's disease based on gait analysis: A survey. *Frontiers in Aging Neuroscience*, *14*. https://doi.org/10.3389/fnagi.2022.916971

Haam, J., & Yakel, J. L. (2017). Cholinergic modulation of the hippocampal region and memory function. *Journal of Neurochemistry*, *142*(S2), 111–121. https://doi.org/10.1111/jnc.14052

Hairi, N. N., Cumming, R. G., Naganathan, V., Handelsman, D. J., Le Couteur, D. G., Creasey, H., Waite, L.M., Seibel, M.J., & Sambrook, P. N. (2010). Loss of muscle strength, mass (sarcopenia), and quality (specific force) and its relationship with functional limitation and physical disability: The concord health and ageing in men project. *Journal of the American Geriatrics Society*, *58*(11), 2055–2062. https://doi.org/10.1111/j.1532-5415.2010.03145.x

Halsband, U., & Lange, R. K. (2006). Motor learning in man: A review of functional and clinical studies. *Journal of Physiology Paris*, *99*(4–6), 414–424. https://doi.org/10.1016/j.jphysparis.2006.03.007

Hebert, L., Julia, B., Judith, M., Paul, S., Robert, W., & Denis, E. (2011). Upper and Lower Extremity Motor Performance and Functional Impairment in Alzheimer's Disease. *NIH Public Access*, *193*(1), 118–125. https://doi.org/10.1016/j.jneumeth.2010.08.011

Im, S., Rushing, B., Wright, A., Softic, D., & Lakhmani, A. (2023). Muscle Tension in Generalized Anxiety Disorder During a Stressful Mental Arithmetic Task. *Research Directs in Psychology and Behavior*, *3*(1). https://doi.org/10.53520/rdpb2023.10776

Iyer, K., & Khan, Z. (2012). Depression – A Review. *Research Journal of Recent Sciences*, *1*, 79–87.

Jankovic, J. (2008). Parkinson's disease: clinical features and diagnosis. *Journal of Neurology, Neurosurgery & Psychiatry*, *79*(4), 368–376. https://doi.org/10.1136/jnnp.2007.131045

Jędrak, P., Krygier, M., Tońska, K., Drozd, M., Kaliszewska, M., Bartnik, E., Soltan, W., Sitek, E.J., Stanisławska-Sachadyn, A.,Limon, J.,Slawek, J., Wegrzyn, G., & Barańska, S. (2017). Mitochondrial DNA levels in Huntington disease leukocytes and dermal fibroblasts. *Metabolic Brain Disease*, *32*(4), 1237–1247. https://doi.org/10.1007/s11011-017-0026-0

Jones, D., Lowe, V., Graff-Radford, J., Botha, H., Barnard, L., Wiepert, D., Murphy, M.C., Murray, M., Senjem, M., Gunter, J., Wiste, H.,Boeve, B., Knopman, D., Peterson, R., & Jack, C. (2022). A computational model of neurodegeneration in Alzheimer's disease. *Nature Communications*, *13*(1), 1643. https://doi.org/10.1038/s41467-022-29047-4

Kasner, E., Hunter, C. A., Ph, D., Kariko, K., & Ph, D. (2013). Increased mitochondrial fission and neuronal dysfunction in Huntington's disease: implications for molecular inhibitors of excessive mitochondrial fission. *NIH Public Access*, *70*(4), 646–656.

Keefover, R. W. (2013). Dementia. *West Virginia Integrated Behavioral Health Conference, 2013 Definitions*, 101–122.

Kravitz, A. V., Freeze, B. S., Parker, P. R., Kay, K., Thwin, M. T., Deisseroth, K., & Kreitzer, A. C. (2010). Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. *Nature*, *466*(7306), 622-626. https://doi.org/10.1038/nature09159

Lamptey, R. N. L., Chaulagain, B., Trivedi, R., Gothwal, A., Layek, B., & Singh, J. (2022). A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics. *International Journal of Molecular Sciences*, *23*(3), 1851. https://doi.org/10.3390/ijms23031851

Larry, N., Zur, G., & Joshua, M. (2024). Organization of reward and movement signals in the basal ganglia and cerebellum. *Nature Communications*, *15*(1), 2119. https://doi.org/10.1038/s41467-024-45921-9

Laukkanen, A., Pesola, A. J., Finni, T., & Sääkslahti, A. (2017). Body Mass Index in the Early Years in Relation to Motor Coordination at the Age of 5–7 Years. *Sports*, *5*(3), 49. https://doi.org/10.3390/sports5030049

Ledoux, É., & Cloutier, E. (2012). Introductory Article. *Relations Industrielles*, *67*(I), 171. https://doi.org/10.7202/1009082ar

Lodi, R., Schapira, A. H. V, Manners, D., Styles, P., Wood, N. W., Taylor, D. J., & Warner, T. T. (2000). Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. *Annals of Neurology*, *48*(1), 72–76. https://doi.org/10.1002/1531-8249(200007)48:1<72::AID-ANA11>3.0.CO;2-I

Mani, S., Jindal, D., Chopra, H., Jha, S.K., Singh, S.K., Ashraf, G.M., Kamal, M., Iqbal, D., Chellappan, D.K., Dey, A., & Dewanjee, S., (2022). ROCK2 inhibition: A futuristic approach for the management of Alzheimer's disease. *Neuroscience & Biobehavioral Reviews*, *142*, 104871. https://doi.org/10.1016/j.neubiorev.2022.104871

Martins, L. A., Schiavo, A., Paz, L. V., Xavier, L. L., & Mestriner, R. G. (2024). Neural underpinnings of fine motor skills under stress and anxiety: A review. *Physiology & Behavior*, *282*, 114593. https://doi.org/10.1016/j.physbeh.2024.114593

Mazzoni, P., Shabbott, B., & Cortés, J. C. (2012). Motor control abnormalities in Parkinson's disease. *Cold Spring Harbor Perspectives in Medicine*, *2*(6), 1–17. https://doi.org/10.1101/cshperspect.a009282

McColgan, P., Seunarine, K. K., Gregory, S., Razi, A., Papoutsi, M., Long, J. D., Mills, J.A., Johnson, E., Durr, A., Ross, R.A. Leavitt, A.R., Stout, J.C., Scahill, R.I., Clark, C.A., Rees, G., Tabrizi, S.J., & Track-On HD Investigators. (2017). Topological length of white matter connections predicts their rate of atrophy in premanifest Huntington's disease. *JCI insight*, *2*(8). https://doi.org/10.1172/jci.insight.92641

McMaster, M. W., Shah, A., Kangarlu, J., Cheikhali, R., Frishman, W. H., & Aronow, W. S. (2024). The Impact of the Apolipoprotein E Genotype on Cardiovascular Disease and Cognitive Disorders. *Cardiology in Review*. https://doi.org/10.1097/CRD.0000000000000703

Meltzer, C. C. (1999). Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. *Neuropsychopharmacology*, *21*, 321. https://doi.org/10.1016/S0893-133X(97)00194-2

Mergl, R., Pogarell, O., Juckel, G., Rihl, J., Henkel, V., Frodl, T., Müller-Siecheneder, F., Kraner, M., Tigges, P., Schröter, A., & Hegerl, U. (2007). *Hand-motor dysfunction in depression: characteristics and pharmacological effects. Clinical EEG and Neuroscience, 38*(2), 82–88. https://doi.org/10.1177/155005940703800210

Moncrieff, J., Cooper, R. E., Stockmann, T., Amendola, S., Hengartner, M. P., & Horowitz, M. A. (2023). The serotonin theory of depression: a systematic umbrella review of the evidence. *Molecular Psychiatry*, *28*(8), 3243–3256. https://doi.org/10.1038/s41380-022-01661-0

Mostoufi, S. M., Afari, N., Ahumada, S. M., Reis, V., & Wetherell, J. L. (2012). Health and distress predictors of heart rate variability in fibromyalgia and other forms of chronic pain. *Journal of Psychosomatic Research*, *72*(1), 39–44. https://doi.org/10.1016/j.jpsychores.2011.05.007

Namiot, E. D., Smirnovová, D., Sokolov, A. V., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2024). Depression clinical trials worldwide: a systematic analysis of the ICTRP and comparison with ClinicalTrials.gov. *Translational Psychiatry*, *14*(1), 315. https://doi.org/10.1038/s41398-024-03031-6

Novak, M. J., & Tabrizi, S. J. (2010). *Huntington's disease. BMJ 340, c3109*. https://doi.org/10.1136/bmj.c3109

Obeso, J. A., Marin, C., Rodriguez-Oroz, C., Blesa, J., Benitez-Temiño, B., Mena-Segovia, J., Rodriguez, M., Olanow, C.W., & Olanow, C. W. (2009). The basal ganglia in Parkinson's disease: Current concepts and unexplained observations. *Annals of Neurology*, *64*(S2), S30–S46. https://doi.org/10.1002/ana.21481

Oschwald, J., Mérillat, S., Jäncke, L., & Seidler, R. D. (2021). Fractional Anisotropy in Selected, Motor-Related White Matter Tracts and Its Cross-Sectional and Longitudinal Associations With Motor Function in Healthy Older Adults. *Frontiers in Human Neuroscience*, *15*. https://doi.org/10.3389/fnhum.2021.621263

Parada, P., Oliva, M., Lázaro, E., Amayra, I., Paz, J. F. L., Martínez, O., Jameton, A., Berrocoso, S., Iglesias, A., & Bárcena, J. E. (2014). Anxiety, depression and self-efficacy in patients with myasthenia gravis. *International Journal of Psychology and Psychological Therapy*, *14*(1), 105–113.

Peralta, V., & Cuesta, M. J. (2017). Motor Abnormalities: From Neurodevelopmental to Neurodegenerative Through "Functional" (Neuro) Psychiatric Disorders. *Schizophrenia Bulletin*, *43*(5), 956–971. https://doi.org/10.1093/schbul/sbx089

Pluess, M., Conrad, A., & Wilhelm, F. H. (2009). Muscle tension in generalized anxiety disorder: A critical review of the literature. *Journal of Anxiety Disorders*, *23*(1), 1–11. https://doi.org/10.1016/j.janxdis.2008.03.016

Ramesh, S., & Arachchige, A. S. P. M. (2023). Depletion of dopamine in Parkinson's disease and relevant therapeutic options: A review of the literature. *AIMS Neuroscience*, *10*(3), 200–231. https://doi.org/10.3934/Neuroscience.2023017

Rana, N., Kapil, L., Singh, C., & Singh, A. (2024). Modeling Huntington's disease: An insight on in-vitro and in-vivo models. *Behavioural Brain Research*, *459*, 114757. https://doi.org/10.1016/j.bbr.2023.114757

Rauch, S. L., Shin, L. M., & Wright, C. I. (2003). Neuroimaging Studies of Amygdala Function in Anxiety Disorders. *Annals of the New York Academy of Sciences*, *985*(1), 389–410. https://doi.org/10.1111/j.1749-6632.2003.tb07096.x

Riley, Z. A., Maerz, A. H., Litsey, J. C., & Enoka, R. M. (2008). Motor unit recruitment in human biceps brachii during sustained voluntary contractions. *The Journal of Physiology*, *586*(8), 2183–2193. https://doi.org/10.1113/jphysiol.2008.150698

Sabandal, P. R., Saldes, E. B., & Han, K. A. (2022). Acetylcholine deficit causes dysfunctional inhibitory control in an aging-dependent manner. *Scientific Reports*, *12*(1), 20903. https://doi.org/10.1038/s41598-022-25402-z

Sabharwal, R. (2014). The link between stress disorders and autonomic dysfunction in muscular dystrophy. *Frontiers in Physiology*, *5 JAN*(January), 1–6. https://doi.org/10.3389/fphys.2014.00025

Sayyid, Z. N., Wang, H., Cai, Y., Gross, A. L., Swenor, B. K., Deal, J. A., Lin, F.R.,Wanigatunga, A.A., Dougherty, R.J., Simonsick, E.M., Ferrucci, A., Schrack, J.A., Resnick, S.M., Agrawal. Y., & Agrawal, Y. (2024). Sensory and motor deficits as contributors to early cognitive impairment. *Alzheimer's & Dementia*, *20*(4), 2653–2661. https://doi.org/10.1002/alz.13715

Scheff, S. W., Neltner, J. H., & Nelson, P. T. (2014). Is synaptic loss a unique hallmark of Alzheimer's disease? *Biochemical Pharmacology*, *88*(4), 517–528. https://doi.org/10.1016/j.bcp.2013.12.028

Smith, C. N., Frascino, J. C., Hopkins, R. O., & Squire, L. R. (2013). The nature of anterograde and retrograde memory impairment after damage to the medial temporal lobe. *Neuropsychologia*, *51*(13), 2709–2714. https://doi.org/10.1016/j.neuropsychologia.2013.09.015

Subramanian, J., & Tremblay, M. È. (2021). Editorial: Synaptic Loss and Neurodegeneration. *Frontiers in Cellular Neuroscience*, *15*. https://doi.org/10.3389/fncel.2021.681029

Tchekalarova, J., &Tzoneva, R. (2023). Oxidative Stress and Aging as Risk Factors for Alzheimer's Disease and Parkinson's Disease: The Role of the Antioxidant Melatonin. *International Journal of Molecular Sciences*, *24*(3), 3022. https://doi.org/10.3390/ijms24033022

Teleanu, R. I., Niculescu, A. G., Roza, E., Vladâcenco, O., Grumezescu, A. M., &Teleanu, D. M. (2022). Neurotransmitters—Key Factors in Neurological and Neurodegenerative Disorders of the Central Nervous System. *International Journal of Molecular Sciences*, *23*(11), 5954. https://doi.org/10.3390/ijms23115954

Tinelli, M., Kanavos, P., & Grimaccia, F. (2016). *The Value of Early Diagnosis and Treatment in Parkinson's Disease*.

van Hagen, M., Piebes, D. G. E., de Leeuw, W. C., Vuist, I. M., van Roon-Mom, W. M. C., Moerland, P. D., & Verschure, P. J. (2017). The dynamics of early-state transcriptional changes and aggregate formation in a Huntington's disease cell model. *BMC Genomics*, *18*(1), 373. https://doi.org/10.1186/s12864-017-3745-z

Verdijk, L. B., Snijders, T., Beelen, M., Savelberg, H. H. C. M., Meijer, K., Kuipers, H., & Van Loon, L. J. C. (2010). Characteristics of muscle fiber type are predictive of skeletal muscle mass and strength in elderly men. *Journal of the American Geriatrics Society*, *58*(11), 2069–2075. https://doi.org/10.1111/j.1532-5415.2010.03150.x

Walker, F. O. (2007). Huntington's disease. *The Lancet*, *369*(9557), 218-228.

Wang, Z., Wang, J., Guo, J., Dove, A., Arfanakis, K., Qi, X., Bennett, D.A., & Xu, W. (2023). Association of Motor Function With Cognitive Trajectories and Structural Brain Differences. *Neurology*, *101*(17). https://doi.org/10.1212/WNL.0000000000207745

Wichmann, T., & Dostrovsky, J. O. (2011). Pathological basal ganglia activity in movement disorders. *Neuroscience*, *198*, 232–244. https://doi.org/10.1016/j.neuroscience.2011.06.048

Wiestler, T., & Diedrichsen, J. (2013). Skill learning strengthens cortical representations of motor sequences. *ELife*, *2013*(2), 1–20. https://doi.org/10.7554/eLife.00801

Wilson, H., De Micco, R., Niccolini, F., & Politis, M. (2017). Molecular imaging markers to track Huntington's disease pathology. *Frontiers in Neurology*, *8*(JAN). https://doi.org/10.3389/fneur.2017.00011

Zeng, X. S., Geng, W. S., Jia, J. J., Chen, L., & Zhang, P. P. (2018). Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease. *Frontiers in Aging Neuroscience*, *10*. https://doi.org/10.3389/fnagi.2018.00109

Zhai, F., Liu, J., Su, N., Han, F., Zhou, L., Ni, J., Yao, M., Zhang, S., Jin, Z., Cui, L., Tian, F., & Zhu, Y. (2020). Disrupted white matter integrity and network connectivity are related to poor motor performance. *Scientific Reports*, *10*(1), 18369. https://doi.org/10.1038/s41598-020-75617-1

Zhai, S., Cui, Q., Simmons, D. V., & Surmeier, D. J. (2023). Distributed dopaminergic signaling in the basal ganglia and its relationship to motor disability in Parkinson's disease. *Current Opinion in Neurobiology*, *83*, 102798. https://doi.org/10.1016/j.conb.2023.102798

Zhang, X. Y., Wu, W. X., Shen, L. P., Ji, M. J., Zhao, P. F., Yu, L., Yin, J., XIE, S.T., Xie, Y.Y., Zhang, .X., Li, H.Z., Zhang, Q.P., Yan, C., Wang, F., Zeeuw, C.D., Wang, J.J. & Zhu, J. N. (2024). A role for the cerebellum in motor-triggered alleviation of anxiety. *Neuron*, *112*(7), 1165-1181.e8. https://doi.org/10.1016/j.neuron.2024.01.007

Zielonka, D., Piotrowska, I., Marcinkowski, J. T., & Mielcarek, M. (2014). Skeletal muscle pathology in Huntington's disease. *Frontiers in Physiology*, *5*(OCT), 1–5. https://doi.org/10.3389/fphys.2014.00380

CHITKARA

Journal of Pharmaceutical Technology, Research and Management

Chitkara University, Saraswati Kendra, SCO 160-161, Sector 9-C, Chandigarh, 160009, India

Volume 12, Issue 1 **April 2024** **ISSN 2321-2217**

Copyright: [©2024 Harshpreet kaur, Navneet Khurana et al.,] This is an Open Access article published in Journal of Pharmaceutical Technology, Research and Management (J. Pharm. Tech. Res. Management) by Chitkara University Publications. It is published with a Creative Commons Attribution- CC-BY 4.0 International License. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.